{
  "symbol": "ABBV",
  "year": 2022,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1773,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.125
  },
  "top_positive": [
    {
      "sent": "Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2022 2021 2022 2021 United States $ 11,410 $ 10,804 5.6 % 5.6 % $ 21,758 $ 20,554 5.9 % 5.9 % International 3,173 3,155 0.6 % 7.6 % 6,363 6,415 (0.8) % 5.3 % Net revenues $ 14,583 $ 13,959 4.5 % 6.1 % $ 28,121 $ 26,969 4.3 % 5.7 % 2022 Form 10-Q | 29 The following table details AbbVie\u2019s worldwide net revenues: Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2022 2021 2022 2021 Immunology Humira United States $ 4,664 $ 4,257 9.6 % 9.6 % $ 8,657 $ 8,164 6.0 % 6.0 % International 699 811 (13.8) % (7.3) % 1,442 1,771 (18.6) % (13.1) % Total $ 5,363 $ 5,068 5.8 % 6.8 % $ 10,099 $ 9,935 1.7 % 2.7 % Skyrizi United States $ 1,079 $ 565 91.1 % 91.1 % $ 1,860 $ 1,046 77.8 % 77.8 % International 173 109 59.1 % 73.9 % 332 202 64.7 % 78.1 % Total $ 1,252 $ 674 85.9 % 88.3 % $ 2,192 $ 1,248 75.7 % 77.9 % Rinvoq United States $ 412 $ 296 39.4 % 39.4 % $ 723 $ 541 33.7 % 33.7 % International 180 82 >100.0 % >100.0 % 334 140 >100.0 % >100.0 % Total $ 592 $ 378 56.3 % 60.7 % $ 1,057 $ 681 55.1 % 59.2 % Hematologic Oncology Imbruvica United States $ 862 $ 1,099 (21.6) % (21.6) % $ 1,736 $ 2,098 (17.2) % (17.2) % Collaboration revenues 283 282 0.5 % 0.5 % 582 551 5.6 % 5.6 % Total $ 1,145 $ 1,381 (17.1) % (17.1) % $ 2,318 $ 2,649 (12.5) % (12.5) % Venclexta United States $ 253 $ 223 13.4 % 13.4 % $ 481 $ 448 7.5 % 7.5 % International 252 212 19.1 % 29.3 % 497 392 26.8 % 36.7 % Total $ 505 $ 435 16.2 % 21.2 % $ 978 $ 840 16.5 % 21.1 % Aesthetics Botox Cosmetic United States $ 449 $ 366 22.4 % 22.4 % $ 862 $ 671 28.3 % 28.3 % International 246 218 12.9 % 19.2 % 474 390 21.5 % 27.7 % Total $ 695 $ 584 18.9 % 21.2 % $ 1,336 $ 1,061 25.8 % 28.1 % Juvederm Collection United States $ 147 $ 196 (24.9) % (24.9) % $ 295 $ 319 (7.5) % (7.5) % International 197 232 (15.0) % (8.1) % 459 430 6.7 % 13.0 % Total $ 344 $ 428 (19.5) % (15.7) % $ 754 $ 749 0.7 % 4.3 % Other Aesthetics United States $ 287 $ 363 (20.9) % (20.9) % $ 572 $ 663 (13.6) % (13.6) % International 45 59 (24.4) % (20.2) % 83 102 (18.3) % (14.3) % Total $ 332 $ 422 (21.4) % (20.8) % $ 655 $ 765 (14.2) % (13.7) % Neuroscience Botox Therapeutic United States $ 557 $ 488 14.2 % 14.2 % $ 1,057 $ 917 15.3 % 15.3 % International 121 115 5.6 % 15.6 % 235 218 8.0 % 16.3 % Total $ 678 $ 603 12.6 % 14.5 % $ 1,292 $ 1,135 13.9 % 15.5 % Vraylar United States $ 492 $ 432 13.9 % 13.9 % $ 919 $ 778 18.1 % 18.1 % Duodopa United States $ 26 $ 25 3.2 % 3.2 % $ 50 $ 50 (1.2) % (1.2) % International 94 102 (7.4) % 2.2 % 191 206 (7.2) % 1.3 % Total $ 120 $ 127 (5.4) % 2.3 % $ 241 $ 256 (6.0) % 0.8 % Ubrelvy United States $ 185 $ 126 47.6 % 47.6 % $ 323 $ 207 56.4 % 56.4 % Qulipta United States $ 33 $ \u2014 n/m n/m $ 44 $ \u2014 n/m n/m Other Neuroscience United States $ 145 $ 167 (13.6) % (13.6) % $ 318 $ 323 (1.7) % (1.7) % International 5 4 9.6 % 12.9 % 9 8 10.4 % 12.6 % Total $ 150 $ 171 (12.9) % (12.8) % $ 327 $ 331 (1.4) % (1.3) % 2022 Form 10-Q | 30 Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2022 2021 2022 2021 Eye Care Lumigan/Ganfort United States $ 60 $ 72 (17.4) % (17.4) % $ 127 $ 138 (8.3) % (8.3) % International 70 77 (8.1) % (0.9) % 143 154 (6.9) % (0.1) % Total $ 130 $ 149 (12.5) % (8.7) % $ 270 $ 292 (7.5) % (3.9) % Alphagan/Combigan United States $ 54 $ 102 (48.5) % (48.5) % $ 124 $ 182 (32.3) % (32.3) % International 38 40 (2.3) % 6.6 % 75 78 (3.1) % 6.0 % Total $ 92 $ 142 (35.6) % (33.1) % $ 199 $ 260 (23.6) % (20.9) % Restasis United States $ 151 $ 312 (51.5) % (51.5) % $ 386 $ 579 (33.2) % (33.2) % International 17 15 14.9 % 24.2 % 28 28 (0.2) % 14.0 % Total $ 168 $ 327 (48.4) % (48.0) % $ 414 $ 607 (31.7) % (31.0) % Other Eye Care United States $ 142 $ 130 9.7 % 9.7 % $ 266 $ 247 7.7 % 7.7 % International 185 171 7.4 % 16.0 % 339 330 2.6 % 10.5 % Total $ 327 $ 301 8.4 % 13.2 % $ 605 $ 577 4.8 % 9.3 % Other Key Products Mavyret United States $ 203 $ 204 0.2 % 0.2 % $ 372 $ 374 (0.4) % (0.4) % International 195 238 (18.0) % (9.8) % 406 483 (15.9) % (8.4) % Total $ 398 $ 442 (9.7) % (5.3) % $ 778 $ 857 (9.1) % (4.9) % Creon United States $ 318 $ 280 13.6 % 13.6 % $ 605 $ 554 9.2 % 9.2 % Linzess/Constella United States $ 247 $ 260 (4.2) % (4.2) % $ 480 $ 475 1.3 % 1.3 % International 8 8 (12.5) % (7.8) % 15 15 (3.8) % 0.7 % Total $ 255 $ 268 (4.5) % (4.4) % $ 495 $ 490 1.1 % 1.2 % All other $ 1,009 $ 1,221 (17.5) % (16.4) % $ 2,220 $ 2,697 (17.8) % (16.8) % Total net revenues $ 14,583 $ 13,959 4.5 % 6.1 % $ 28,121 $ 26,969 4.3 % 5.7 % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis.",
      "score": 0.996
    },
    {
      "sent": "AbbVie intends to continue to advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii)\u00a0growing revenues by leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0expanding operating margins; and (v)\u00a0returning cash to shareholders via a strong and growing dividend while also reducing debt.",
      "score": 0.9803
    },
    {
      "sent": "AbbVie\u2019s long-term success depends to a great extent on its ability to continue to discover and develop innovative products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies.",
      "score": 0.9186
    }
  ],
  "top_negative": [
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    }
  ],
  "forward_snippets": [
    "AbbVie intends to continue to advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii)\u00a0growing revenues by leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0expanding operating margins; and (v)\u00a0returning cash to shareholders via a strong and growing dividend while also reducing debt.",
    "Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands.",
    "Throughout the pandemic, AbbVie has followed health and safety guidance from state and local health authorities and implemented safety measures for those employees who are returning to the workplace.",
    "AbbVie\u2019s pipeline currently includes approximately 80 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care.",
    "Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands."
  ]
}